About Us Resources Catalysts Start Free Trial →

Loading…

Day Trader Sniper provides algorithmic alerts and analysis, not trade advice.
Not financial advice. Trade at your own risk.

Quick Links

Download The App Resources Market Feed Stocks

Catalysts About Us Support Privacy policy Terms of use

©2026 Day Trader Sniper - all rights reserved

Home›Catalysts›Regulatory and Clinical

Catalyst Category

Regulatory and Clinical

Live feed of every catalyst classified under Regulatory and Clinical.

CATALYSTS IN FEED

168

AVG MAX MOVE

+116.8%

POSITIVE MOVES

100%

LARGEST MOVE

+664.1%

DSMB Efficacy Met FDA 510(k) Cleared FDA Approval FDA Fast Track FDA Meeting FDA Meeting Granted Generic Drug Approved Inconclusive Topline Results IND Cleared for Study IND Filed NDA Resubmission Orphan Drug Designation Positive Subgroup Data Positive Topline Results Primary Endpoint Met SPA Agreement Study Complete Trial Enrollment Complete

Range–

Showing 7 of 168

Regulatory and ClinicalMay 27, 2025 · 10:40am ET

IMNNImunon, Inc. Common Stock

Imunon Announces Acceptance of IMNN-001 Abstract for ESMO Gynaecological Cancers Congress 2025

The abstract highlights data from the Phase 2 OVATION 2 Study.

Be first on the next Regulatory and Clinical catalyst.

Day Trader Sniper alerts you the instant a setup like this triggers.

Download Free →

Max move

+180.6%

RVOL

2.9x

Max high

$31.30

Fuel

5h 18m

Regulatory and ClinicalMay 27, 2025 · 10:40am ET

IMNNImunon, Inc. Common Stock+180.6%

Imunon Announces Acceptance of IMNN-001 Abstract for ESMO Gynaecological Cancers Congress 2025

RVOL

2.9x

Max high

$31.30

Fuel

5h 18m

Regulatory and ClinicalMay 22, 2025 · 7:59pm ET

IMNNImunon, Inc. Common Stock

Imunon Announces Up To $9.75 Million Private Placement Priced At-The-Market

The placement includes $3.25 million upfront and up to an additional $6.5 million.

Regulatory and ClinicalMay 22, 2025 · 7:59pm ET

IMNNImunon, Inc. Common Stock+256.2%

Imunon Announces Up To $9.75 Million Private Placement Priced At-The-Market

Regulatory and ClinicalMay 19, 2025 · 7:50pm ET

KTTAPasithea Therapeutics Corp.

Pasithea Therapeutics Announces Preclinical Data on PAS-004

PAS-004 shows inhibition of ETS2 signaling, a key driver of inflammation.

Regulatory and ClinicalMay 19, 2025 · 7:50pm ET

KTTAPasithea Therapeutics Corp.+56.9%

Pasithea Therapeutics Announces Preclinical Data on PAS-004

Regulatory and ClinicalMay 19, 2025 · 3:59pm ET

NRXSNeuraxis, Inc.

Neuraxis, Inc. Receives FDA 510(K) Clearance for IB-Stim

Clearance granted for treatment of pediatric functional abdominal pain and related symptoms.

Regulatory and ClinicalMay 19, 2025 · 3:59pm ET

NRXSNeuraxis, Inc.+211.6%

Neuraxis, Inc. Receives FDA 510(K) Clearance for IB-Stim

Regulatory and ClinicalMay 6, 2025 · 7:45pm ET

PHIOPhio Pharmaceuticals Corp. Common Stock

Phio Pharmaceuticals Corp. Announces Pathology Results in Third Dose Cohort of Skin Cancer Clinical Trial

Company revealed findings from the INTASYL PH-762 trial.

Regulatory and ClinicalMay 6, 2025 · 7:45pm ET

PHIOPhio Pharmaceuticals Corp. Common Stock+54.3%

Phio Pharmaceuticals Corp. Announces Pathology Results in Third Dose Cohort of Skin Cancer Clinical Trial

Regulatory and ClinicalMay 6, 2025 · 3:52pm ET

TOVXTheriva Biologics, Inc.

Theriva Biologics Announces Pricing Of $7.5M Public Offering And Reports VIRAGE Phase 2b Trial Findings

Theriva Biologics, Inc. issued a press release detailing two significant announcements.

Regulatory and ClinicalMay 6, 2025 · 3:52pm ET

TOVXTheriva Biologics, Inc.+105.0%

Theriva Biologics Announces Pricing Of $7.5M Public Offering And Reports VIRAGE Phase 2b Trial Findings

Regulatory and ClinicalMay 5, 2025 · 6:52pm ET

GLMDGalmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Announces Aramchol Enhances Regorafenib Effects in Oncology Studies

Company revealed positive results from initial oncology studies.

Regulatory and ClinicalMay 5, 2025 · 6:52pm ET

GLMDGalmed Pharmaceuticals Ltd.+60.3%

Galmed Pharmaceuticals Ltd. Announces Aramchol Enhances Regorafenib Effects in Oncology Studies

1
…
19
20
21
…
24

RVOL

5.8x

Max high

$19.30

Fuel

3h 30m

RVOL

4.6x

Max high

$1.44

Fuel

11m

RVOL

13.1x

Max high

$7.01

Fuel

28m

RVOL

2.6x

Max high

$2.67

Fuel

10m

RVOL

14.3x

Max high

$2.87

Fuel

11m

RVOL

6.3x

Max high

$16.80

Fuel

6m